7 matches for your search in the start-up spotlight
rss
The world is facing an unprecedented antimicrobial resistance crisis with regular antibiotics losing their efficacy against antibiotic-resistant bacteria. Obulytix is a biotechnology company focused on the discovery and development of a groundbreaking class of enzyme-based antibiotics to combat ...
Glox Therapeutics is developing a pipeline of engineered precision bacteriocins targeting pathogens that cause serious infections associated with high levels of antimicrobial resistance (AMR) and mortality. These novel precision antibiotics have potent narrow-spectrum activity to target ...
Santero Therapeutics SRL is a spin-off biotech from the Université Libre de Bruxelles founded in 2021 by Professors Cédric Govaerts, PhD and Abel Garcia-Pino, PhD The company is anchored in more than a decade of fundamental research carried out in the labs of the Founders. Santero Therapeutics ...
Selmod is a Swiss biotech start-up and was founded in May 2016 in Basel, Switzerland. Selmod develops innovative antibiotics for the treatment of life-threatening, multi-drug resistant infections. The company’s focus is on discovery and early clinical development of small molecules and peptides ...
The Swiss start-up company Juvabis designs next-generation aminoglycoside antibiotics that withstand mechanisms of bacterial drug-resistance and at the same time display superior tolerability due to increased target selectivity by rational design. Juvabis has been founded around a proprietary ...
BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company's award-winning TRIC ...
